Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiretroviral therapy
non-nucleoside reverse transcriptase inhibitor |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2011 |
| gptkbp:ATCCode |
J05AG05
|
| gptkbp:brand |
gptkb:Edurant
|
| gptkbp:CASNumber |
500287-72-9
|
| gptkbp:chemicalClass |
diarylpyrimidine
|
| gptkbp:combinationTherapy |
gptkb:Complera
gptkb:Odefsey |
| gptkbp:developedBy |
gptkb:Janssen_Pharmaceutica
|
| gptkbp:eliminationHalfLife |
45 hours
|
| gptkbp:hasMolecularFormula |
C22H18N6
|
| https://www.w3.org/2000/01/rdf-schema#label |
rilpivirine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits HIV-1 reverse transcriptase
|
| gptkbp:metabolism |
liver (CYP3A4)
|
| gptkbp:pregnancyCategory |
B (US)
B1 (Australia) |
| gptkbp:proteinBinding |
99.7%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:depression
nausea headache rash insomnia |
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:NNRTIs
|
| gptkbp:bfsLayer |
5
|